Press Releases Print Email
All Releases
View Summary VIVUS Reports Third Quarter 2017 Financial Results
Nov 7, 2017
PDF 34.7 KB Add to Briefcase
View Summary VIVUS Completes Tacrolimus Pre-IND Meeting With FDA
Nov 2, 2017
PDF 11.8 KB Add to Briefcase
View Summary VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
Oct 31, 2017
PDF 10.3 KB Add to Briefcase
View Summary VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
Sep 6, 2017
PDF 12.1 KB Add to Briefcase
View Summary VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
Sep 5, 2017
PDF 13.4 KB Add to Briefcase
View Summary VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
Aug 30, 2017
PDF 12.6 KB Add to Briefcase
View Summary VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
Aug 22, 2017
PDF 9.8 KB Add to Briefcase
View Summary VIVUS Reports Second Quarter 2017 Financial Results
Aug 3, 2017
PDF 33.7 KB Add to Briefcase
View Summary VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
Jul 5, 2017
PDF 12.7 KB Add to Briefcase
View Summary Thomas B. King Joins VIVUS' Board of Directors
May 24, 2017
PDF 11.4 KB Add to Briefcase
View Summary VIVUS Reports 2017 First Quarter Financial Results
May 3, 2017
PDF 30.9 KB Add to Briefcase
View Summary VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
Apr 25, 2017
PDF 10.1 KB Add to Briefcase
View Summary VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
Mar 27, 2017
PDF 14.6 KB Add to Briefcase
View Summary VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 8, 2017
PDF 35.3 KB Add to Briefcase
View Summary VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference
Feb 28, 2017
PDF 10.0 KB Add to Briefcase
View Summary VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
Jan 9, 2017
PDF 13.8 KB Add to Briefcase
View Summary VIVUS Reports 2016 Third Quarter Financial Results
Nov 9, 2016
PDF 36.9 KB Add to Briefcase
View Summary VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference
Oct 26, 2016
PDF 10.2 KB Add to Briefcase
View Summary VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
Oct 3, 2016
PDF 15.8 KB Add to Briefcase
View Summary VIVUS Extends Return Date of STENDRA Commercial Rights
Aug 29, 2016
PDF 14.6 KB Add to Briefcase
Showing 1-20 of 434 Page: 1 2 3 ... 22  Next 20
= add release to Briefcase